Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07832227 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial

Name: Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial — clinical trial record (NCT07832227)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SIERRA

StatusNot Yet Recruiting

PhasePhase 2

SponsorDana-Farber Cancer Institute

Started2026-12-01

View on ClinicalTrials.gov ↗

Dana-Farber Cancer Institute

287 trials monitored

See 33 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

Endometrial Cancer

629 trials monitored

See 39 trials at risk

This is a phase 2, interventional treatment trial evaluating imlunestrant, abemaciclib, and selinexor in two separate patient cohorts: low grade serous ovarian cancer and endometrioid endometrial cancer. The study is non-randomized and open-label. Treatment is administered in the outpatient setting, with a 14-day Cycle 0 followed by 28-day treatment cycles.

Trial Details

NCT Number	NCT07832227
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Eli Lilly and Company, Karyopharm Therapeutics Inc
Conditions	Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
Enrollment	60 participants
Start Date	2026-12-01
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-21